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Abstract 
The purpose of this study was to examine the feasibility of collecting quantitative measures from 
parents or other caregivers about the symptoms present in their children with autism spectrum disorders 
that are of most concern to them and may be ameliorated through intervention. These symptoms were 
measured by asking questions about frequency, duration, and interference with daily function and family 
life. The most common symptoms identified by parents were problems with communication/speech and 
socialization impairments. Parents and caregivers were able to provide quantitative information, and 
their responses appeared to describe things that would be sensitive to change. The Parent-Nominated 
Symptoms Questionnaire seems to be a reliable measure when creating interventions and provides 
variability of symptoms.  
 
Introduction 
Autism spectrum disorders (ASD) comprise a set of developmental disorders that are 
characterized by impairments in social and communication skills as well as the presence of restrictive, 
repetitive, and stereotypic behaviors (American Psychiatric Association, 1994). A characteristic of the 
disorder is the heterogeneity of its presentation. A challenge raised by this heterogeneity is that it is 
difficult to measure symptoms and changes in symptoms over time for a group of children with ASD 
using a single measure (Levy et al., 2009). This is particularly a problem in treatment studies. A second 
challenge in measuring outcomes for children with psychiatric and developmental disabilities in general 
is the measures’ ecological validity—that is, the extent to which they measure constructs that relate to 
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functioning in real-world settings. To address both challenges, researchers have sometimes turned to 
“parent- nominated symptoms” to assess outcomes in treatment trials. 
Parent-nominated symptoms are the target symptoms that parents and caregivers identify in their 
children that are of most concern to them. They are measured by frequency, duration, and interference 
with daily function or family life. Parents are asked to provide detail about the symptoms their children 
exhibit that cause them the most concern. It is likely that standardized scales, though very helpful and 
reliable, can overlook certain domains as well as the exact items that are most important to the child and 
to parents and caregivers (Arnold et al., 2003). Parents and caregivers may be an important source of 
information regarding symptoms that their children exhibit that are of most concern to them and their 
family and may represent intervention targets.  
The strategy of collecting information on parent-nominated symptoms has been used in 
pharmacological studies of children with ASD. For example, an individualized target symptom 
assessment originally described by Arnold et al. (1972) and used in later studies in attention-
deficit/hyperactivity disorder (Arnold et al. 1976, 1978) was used in the Research Units on Pediatric 
Psychopharmacology (RUPP) Autism Network 8-week double-blind trial of risperidone versus placebo 
(Arnold et al. 2003). Clinicians interviewed parents at baseline and asked them to identify target 
symptoms that were assessed again at the end of the study. The target symptoms assessment was used as 
an outcome measure and was highly correlated with other standardized measures used.  
The current study sought information from parents which clinicians may rate in order to track the 
changes in parent-nominated symptoms. This was done to take a qualitative measure and turn it into a 
quantitative measure. The study also tested the feasibility of refining and replicating this strategy in a 
behavioral study while shedding light on key symptoms that were relevant to parents and caregivers and 
could be important targets for intervention and measuring intervention effects. The drug trial sampled 
families that were of a higher socio-economic status (SES) and that had higher rates of literacy 
competency. The participants in the present behavioral study, on the other hand, were of lower SES, and 
many had literacy issues. Replicating the strategy from the drug trial was important in order to gain 
information from this underrepresented population. 
 
Methods 
Data were collected from the parents and caregivers of children that were enrolled in an ongoing 
randomized trial of a behavioral intervention, the Autism Instructional Methods Study (AIMS), taking 
place in the School District of Philadelphia. The sample included only those children still in the study 
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who have been flooring, or scoring the lowest possible score, on the standardized instruments being used 
as outcome measures in AIMS. Children in the lower-functioning autism population that are unable to 
complete standardized instruments are often not represented in autism studies, so it was important to 
focus mainly on them in this study.  
Eighteen families were contacted for semi-structured phone interviews. They were asked 
questions about the domains of communicative and social impairments as well as maladaptive 
behaviors. This was done to ensure that the key characteristics that warrant a diagnosis of ASD were 
addressed. A phone script (see Appendix) was created for use when conducting phone interviews with 
parents and caregivers as well as a verbal consent form that was read to interviewees before questions 
about parent-nominated symptoms were asked.  
Parents and caregivers were asked questions about the symptoms they are most concerned with. 
These questions asked about frequency and duration of the symptoms and how they interfere with daily 
life of the parents/caregivers and the family. The information was elicited by specific questions if 
necessary (“How often? How long each time? How many hours a day? How does it interfere with daily 
activities?”).  
 
Results 
Parents and caregivers made 36 reports (each parent reported 2 symptoms). The symptoms that 
they identified included problems with communication/speech (10), socialization/social interaction (7), 
hyperactivity/over activeness (5), tantrums/aggressiveness (4), other behaviors (4), meltdowns (2), 
strange hand gestures (2), and following directions/comprehension (2). The breakdown of symptoms is 
shown in the figure below: 
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The reports parents and caregivers made provided quantifying information about their children’s 
symptoms that included the number of times they occur a day and how long they last. Their 
quantifications may lend themselves to measuring change in future studies. There were similarities and 
differences between the drug and behavioral trials. Parents and caregivers reported issues of tantrums 
and other aberrant behaviors in both. The drug trial focused on aberrant behavior, however, while issues 
of communication and social interaction arose mainly in the behavioral trial.  
 
Limitations 
There were a few limitations to the study. First, there were only 18 families included in the study 
and this small sample size may not accurately reflect what is going on in the larger population of 
children with ASD. In addition, the Arnold et al. (2003) study included a group of clinicians that rated 
the symptoms identified by parents and caregivers at baseline and again at the end of the trial, with the 
same symptoms being rated at both intervals. This study did not have ratings from a group of clinicians, 
and therefore there was no measure of change in the symptoms over time and no way to ensure that the 
results are statistically significant. This is the next step in behavioral studies that collect information of 
parent-nominated symptoms. Finally, the parent-identified symptoms were not validated against any 
other measure. 
 
Implications 
The addition of a Parent-Nominated Symptoms Questionnaire seems to provide invaluable 
information and insight to studies involving children with ASD. Often, the problems the families are 
talking about involve the absence of something rather than the presence of something. This is why it is 
important to speak with people who interact with these children on a regular basis and can speak on all 
of their issues that standardized measures cannot detect—in this case, the parents and caregivers. The 
parent-nominated symptoms measurement can be correlated with the information collected from the 
standardized scales and may provide an ecologically valid, statistically reliable outcome measure for 
behavioral intervention trials.  Universal interventions for children with autism that are focused on 
learning need to change how parent-nominated symptoms are elicited. If we can rely on these measures, 
we can reduce bias associated with SES. 
 
 
 
4
Penn McNair Research Journal, Vol. 2 [2010], Iss. 1, Art. 6
http://repository.upenn.edu/mcnair_scholars/vol2/iss1/6
 
Parent-Nominated Symptoms / Dabel   5 
References 
 
American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, 
DC: American Psychiatric Association 
 
Arnold, L. E.; Christopher, J.; Huestis, R.; Smeltzer, D. J. (1978). “Methylphenidate vs. d-amphetamine vs. caffeine in MBD: 
controlled comparison by placebo washout design with Bayes analysis.” Archives of General Psychiatry 35:463-473 
 
Arnold, L. E.; Huestis R.D.; Smeltzer D.; Scheib, J.; Wemmer, D.; Colner, G. (1976). “Levoamphetamine vs. 
dextroamphetamine in MBD: replication, time response and differential effect by diagnostic group and family rating.” 
Archives of General Psychiatry 33:292-301 
 
Arnold, L. E.; Vitello, B.; McDougle, C.; Scahill, L.; Shah, B.; Gonzalez, N. M.; Chuang, S.; Davies, M.; Hollway, J.; Aman, 
M. G.; Cronin, P.; Koenig, K.; Kohn, A. E.; McMahon, D. J.; Tierney, E. (2003). “Parent-Defined Target Symptoms 
Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical Trials.” Journal of the American Academy 
of Child and Adolescent Psychiatry 42:12 1443-1449 
 
Arnold, L. E.; Wender, P. H.; McCloskey, K.; Snyder, S. (1972). “Levoamphetamine and dextroamphetamine: comparable 
efficacy in the hyperkinetic syndrome: assessment by target symptom.” Archives of General Psychiatry 27:816-822 
 
Levy, S. E.; Mandell, D. S.; Schultz, R. T. (2009). “Autism.” Lancet 374:1627-1638. 
 
 
 
Appendix: Parent-Nominated Symptoms Phone Script  
 
Hello, my name is Vanessa Dabel and I am part of the Philly AIMS Team (the study taking place with the University of 
Pennsylvania that your child, *Child’s name,* is participating in). I wanted to conduct a phone interview with you about 
(child’s name)’s symptoms that you think are the most concerning. First, thank you for completing the surveys we sent. I’m 
calling because we want to make sure that we learn about symptoms (child’s name) has that are most important to you. This 
interview should take about 5 minutes. Do you have a few minutes to talk? (If no: Is there another time that would be best for 
you? Is [     time] ok? Home or cell #?) Before we start, the University of Pennsylvania requires that I read a brief statement 
to make sure you understand the study and make sure that you are willing to participate.  
 
Consent Form portion 
The purpose of the study is to learn more about the symptoms in children with autism that parents identify as the most 
concerning. You will be asked to complete a phone interview now. 
 
There are no benefits to participating in this research study. Participation in this study is voluntary and all information that 
you provide will be kept strictly confidential. You are not obligated to participate in this study and it will not affect your 
participation in the AIMS project. If you decide after agreeing to participate in the study that you would not like to be 
involved anymore, you can stop at anytime. 
 
If you have questions, concerns or complaints regarding your participation in this research study or if you have any 
questions about your rights as a research subject, you can contact the Principal Investigator (PI), David Mandell, at xxx-xxx-
xxxx or you can contact me, Vanessa Dabel, at xxx-xxx-xxxx. 
If you have any questions or if there is something you do not understand, please ask.  
 
Are you still willing to participate in this study? (If they respond yes, go forth with the rest of the script. If they say no, reply 
“Thank you and have a great day.”) 
 
What one or two symptoms are you most concerned about for [child’s name]? What thing does he do, what problem does he 
have that causes you the most concern or problems? How often do they occur? How long each time? How many hours a day? 
How does it interfere with daily activities?  
 
Thank you for your time!  
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